---
title: "BPC-157"
canonical_url: https://peptidelibrary.app/library/bpc-157
description: "Synthetic gastric pentadecapeptide widely sold as a research chemical for tissue-repair models. Not FDA-approved. FDA lists it among bulk substances nominated for compounding and then withdrawn, and FDA staff's May 2026 briefing proposed not adding it to the 503A Bulks List, citing limited safety and effectiveness data. WADA prohibits BPC-157 under S0."
updated: 2026-10-30
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# BPC-157

BPC-157 (also called Body Protection Compound 157 or PL 14736) is a research peptide in the Wound Healing / Cytoprotective class. Preclinical work reports angiogenesis, nitric-oxide modulation, and growth-factor (VEGFR2, FAK) signaling that may support tendon, muscle, and gut mucosal healing in animals.

Synthetic gastric pentadecapeptide widely sold as a research chemical for tissue-repair models. Not FDA-approved. FDA lists it among bulk substances nominated for compounding and then withdrawn, and FDA staff's May 2026 briefing proposed not adding it to the 503A Bulks List, citing limited safety and effectiveness data. WADA prohibits BPC-157 under S0.

Also known as: Body Protection Compound 157, PL 14736, Bepecin.

Categories: Muscle/Recovery, Experimental.

## Classification

- Type: Healing / Regenerative
- Mechanism class: Wound Healing / Cytoprotective
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Preclinical work reports angiogenesis, nitric-oxide modulation, and growth-factor (VEGFR2, FAK) signaling that may support tendon, muscle, and gut mucosal healing in animals. Robust randomized human efficacy data are lacking.

Targets: VEGFR2 / FAK pathways, Nitric oxide system, GI mucosa.

Origin: Partial sequence of human gastric juice protein BPC.

## Properties

- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Length: 15
- Molecular formula: C62H98N16O22
- Molecular weight: 1,419.5 g/mol
- CAS number: 137525-51-0
- Half-life: Not established in humans
- Studied routes: Rectal enema, Intra-articular, Intravesical, Intravenous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 5
- Controlled human trials: 2
- Preclinical sources: 3
- Latest source: 2025

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Ruenzi M, et al. A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase II Study of PL 14736 Enema in the Treatment of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2005;128:A584 (meeting abstract, as reviewed in FDA's briefing document of May 11, 2026). 2005. Controlled human trial. Population: Subjects with mild to moderate ulcerative colitis (n=53 randomized, 46 completed). Mean Disease Activity Index change was -3.2 points with BPC-157 and -1.6 with placebo, an estimated difference of 1.6 points (95% CI -4.84 to 1.62); the interval includes zero. FDA calls the data inadequate to support efficacy or safety: the abstract is the only report, and it lacks details of the endpoint, inclusion criteria, statistical methods and post-treatment follow-up. [Source](https://www.fda.gov/media/193343/download)
2. Veljaca M, et al. Safety, Tolerability and Pharmacokinetics of PL 14736, a Novel Agent for Treatment of Ulcerative Colitis, in Healthy Male Volunteers. Gut. 2003;51:A309 (meeting abstract, with a 2002 IUPHAR-GI abstract; as reviewed in FDA's briefing document of May 11, 2026). 2002. Controlled human trial. Population: Healthy subjects (n=32 randomized, 24 received BPC-157). A study of tolerability in healthy subjects, so it cannot show whether BPC-157 works. The abstracts report no significant adverse events attributed to treatment; headache and flatulence were the most frequent, with no obvious difference from placebo. BPC-157 was not detected in plasma, or was mostly below the assay's limit. FDA notes that the authors gave limited safety information. [Source](https://www.fda.gov/media/193343/download)
3. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. 2021. Human study (early or uncontrolled). Population: Patients with knee pain of mixed causes (n=16 reached by phone of 17 treated; 12 received BPC-157 alone, 4 with thymosin beta-4). By phone survey, 11 of 12 patients given BPC-157 alone reported improved knee pain, and 7 of those 12 reported that relief lasted 6 months to 1 year. With thymosin beta-4, 3 of 4 improved (14 of 16 overall). The paper reports no adverse events. There was no control group, patients paid for treatment, causes of pain differed, only 4 of 16 had an MRI, and outcomes were subjective with no objective testing. [Source](https://pubmed.ncbi.nlm.nih.gov/34324435/)
4. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. 2024. Human study (early or uncontrolled). Population: Women with moderate to severe interstitial cystitis who had not responded to pentosan polysulfate (n=12). On a self-rated Global Response Assessment, 10 of 12 women reported complete symptom resolution and 2 of 12 reported 80% improvement, with no adverse events reported. There was no control group, patients paid for treatment, and the authors note the small sample, the lack of a sham control and the absence of biopsies. [Source](https://pubmed.ncbi.nlm.nih.gov/39325560/)
5. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. 2025. Human study (early or uncontrolled). Population: Relatively healthy adults aged 58 and 68 (n=2), both with earlier intravenous BPC-157 use. The authors report no side effects and no meaningful change in vital signs or blood tests, apart from a small creatine kinase rise they call clinically insignificant. The paper concludes that this showed safety, but 2 self-paying participants who had already used it, no control group and follow-up ending 24 hours after the second infusion are too little to establish safety. [Source](https://pubmed.ncbi.nlm.nih.gov/40131143/)
6. NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial. Human study (early or uncontrolled). Population: Healthy volunteers (n=42). Safety and pharmacokinetics. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT02637284)
7. NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair. Human study (early or uncontrolled). Population: Adults with acute hamstring muscle strain (planned n=120). Hamstring muscle strain repair. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT07437547)
8. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals (Basel). 2025. 2025. Preclinical: animal or lab study. Population: Rodent models. Gastrointestinal, tendon, ligament and wound healing. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/40005999/)
9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. 2025. Preclinical: animal or lab study. Population: Studies reviewed were preclinical. Musculoskeletal healing. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/40756949/)
10. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. 2022. Preclinical: animal or lab study. Population: Rats and beagle dogs. Elimination half-life was under 30 minutes in both species; after a single intravenous dose it averaged 15.2 minutes in rats and 5.27 minutes in dogs. These are animal figures and do not give a human half-life. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/36588717/)

### Registered trials

- [NCT02637284](https://clinicaltrials.gov/study/NCT02637284)
- [NCT07437547](https://clinicaltrials.gov/study/NCT07437547)

## Safety

Side effects: Injection site irritation; Nausea (rare); Fatigue (rare).

Risks: Banned by WADA; Angiogenic effects in cancer.

Contraindications: Active cancer; Pregnancy.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

BPC-157 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is BPC-157?

Synthetic gastric pentadecapeptide widely sold as a research chemical for tissue-repair models. Not FDA-approved. FDA lists it among bulk substances nominated for compounding and then withdrawn, and FDA staff's May 2026 briefing proposed not adding it to the 503A Bulks List, citing limited safety and effectiveness data. WADA prohibits BPC-157 under S0. Preclinical work reports angiogenesis, nitric-oxide modulation, and growth-factor (VEGFR2, FAK) signaling that may support tendon, muscle, and gut mucosal healing in animals. Robust randomized human efficacy data are lacking.

### How does BPC-157 work?

Preclinical work reports angiogenesis, nitric-oxide modulation, and growth-factor (VEGFR2, FAK) signaling that may support tendon, muscle, and gut mucosal healing in animals. Robust randomized human efficacy data are lacking.

### Is BPC-157 FDA approved?

No. BPC-157 is not approved by the FDA for any indication and is categorised as research-only. FDA staff reviewed the published evidence in 2026 for the 503A compounding list, not as a drug application, and proposed not adding it. Published research should be read as investigation rather than established use. FDA's compounding lists show 503A nomination: Previously in Category 2; nomination withdrawn by the nominators.

### What is the amino acid sequence of BPC-157?

BPC-157 has the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, giving a chain of 15 amino acids. Its molecular formula is C62H98N16O22.

### Is BPC-157 banned in sport?

BPC-157 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

## References

- [USADA — BPC-157 prohibited (S0)](https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/)
- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review — Pharmaceuticals (Basel), 2025](https://pubmed.ncbi.nlm.nih.gov/40005999/)
- [Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS J, 2025](https://pubmed.ncbi.nlm.nih.gov/40756949/)
- [Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — Curr Rev Musculoskelet Med, 2025](https://pubmed.ncbi.nlm.nih.gov/40789979/)
- [Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review — Pharmaceuticals (Basel), 2024](https://pubmed.ncbi.nlm.nih.gov/39204186/)
- [Pentadecapeptide BPC 157 and the central nervous system — Neural Regen Res, 2022](https://pubmed.ncbi.nlm.nih.gov/34380875/)
- [FDA briefing document: BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026](https://www.fda.gov/media/193343/download)
- [FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (April 22, 2026)](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)
- [Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain — Altern Ther Health Med, 2021](https://pubmed.ncbi.nlm.nih.gov/34324435/)
- [Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study — Altern Ther Health Med, 2024](https://pubmed.ncbi.nlm.nih.gov/39325560/)
- [Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — Altern Ther Health Med, 2025](https://pubmed.ncbi.nlm.nih.gov/40131143/)
- [Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs — Front Pharmacol, 2022](https://pubmed.ncbi.nlm.nih.gov/36588717/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
